CART cell therapy for prostate cancer: status and promise.
CAR-T cells
adoptive immunotherapy
prostate cancer
review
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
epublish
Résumé
In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells. In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.
Identifiants
pubmed: 30655675
doi: 10.2147/OTT.S185556
pii: ott-12-391
pmc: PMC6322708
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
391-395Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Oncogene. 2000 Mar 2;19(10):1288-96
pubmed: 10713670
Prostate. 2000 May 1;43(2):150-7
pubmed: 10754531
Cancer Res. 2000 Oct 1;60(19):5522-8
pubmed: 11034097
Keio J Med. 2003 Jun;52(2):86-91
pubmed: 12862359
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
Mol Cancer Ther. 2008 Jul;7(7):2142-51
pubmed: 18645024
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
pubmed: 19211796
Rev Urol. 2009 Winter;11(1):16-27
pubmed: 19390671
Immunotherapy. 2011 Jan;3(1):33-48
pubmed: 21174556
Expert Opin Biol Ther. 2011 Jul;11(7):855-73
pubmed: 21463133
Cancer Res. 2011 Sep 1;71(17):5697-706
pubmed: 21742772
BJU Int. 2012 Jun;109 Suppl 6:22-32
pubmed: 22672122
Nat Biotechnol. 2013 Jan;31(1):71-5
pubmed: 23242161
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):123-31, S1
pubmed: 23295316
Prostate. 2014 Feb;74(3):286-96
pubmed: 24174378
Hum Gene Ther. 2014 Dec;25(12):1003-12
pubmed: 24694017
Cancer Immunol Res. 2015 Jan;3(1):68-84
pubmed: 25358763
Immunol Rev. 2015 Jan;263(1):68-89
pubmed: 25510272
BioDrugs. 2015 Apr;29(2):75-89
pubmed: 25859858
Int J Pharm. 2017 Nov 5;532(2):813-824
pubmed: 28764981
Eur Urol. 2018 May;73(5):648-652
pubmed: 29275833
Oncoimmunology. 2017 Oct 16;7(2):e1380764
pubmed: 29308300
Mol Ther. 2018 Jul 5;26(7):1855-1866
pubmed: 29807781
J Biomed Mater Res A. 2018 Dec;106(12):3152-3164
pubmed: 30194716
Histochem J. 1981 Nov;13(6):961-73
pubmed: 6175605
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40
pubmed: 9465086